Wet Age-related Macular Degeneration Clinical Trials

78 clinical trials for Wet Age-related Macular Degeneration across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• MMP-9 Inhibition for Recalcitrant Wet AMD — RECRUITING · PHASE2
• Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) — RECRUITING · PHASE3
• Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) — RECRUITING · PHASE1
• A Long-term Follow up Study of EXG102-031 in Participants With wAMD — RECRUITING
• Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals — RECRUITING · PHASE4
• Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD — RECRUITING
• A PHASE 1/2A OPEN-LABEL STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF NG101 AAV GENE THERAPY IN SUBJECTS WITH WET AGE-RELATED MACULAR DEGENERATION — RECRUITING · PHASE1
• Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of anti VEGF-A therapy. — COMPLETED · PHASE4
• Evaluation of PAN-90806 Eye Drops in Healthy Subjects — NOT_YET_RECRUITING · PHASE1
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 — ACTIVE_NOT_RECRUITING · PHASE3
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — ACTIVE_NOT_RECRUITING · PHASE3
• Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD — ACTIVE_NOT_RECRUITING · PHASE3
• NT-101 Topical Ophthalmic Solution in Patients With Wet AMD — COMPLETED · PHASE1
• A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD (EYP-1901-302) — TERMINATED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK — ACTIVE_NOT_RECRUITING · PHASE3
• Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD — ACTIVE_NOT_RECRUITING · PHASE2
• Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] — ACTIVE_NOT_RECRUITING
• A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) — COMPLETED · PHASE3
• User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems — NOT_YET_RECRUITING
• Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients — ACTIVE_NOT_RECRUITING
• CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking — COMPLETED
• Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD — ACTIVE_NOT_RECRUITING · NA
• Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) — COMPLETED · PHASE2
• Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD — NOT_YET_RECRUITING · PHASE1
• Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops — COMPLETED · PHASE1
• High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) — NOT_YET_RECRUITING · PHASE3
• AAVCAGsCD59 for the Treatment of Wet AMD — COMPLETED · PHASE1
• To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) — NOT_YET_RECRUITING · PHASE1
• Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD — ACTIVE_NOT_RECRUITING · PHASE1
• Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD — NOT_YET_RECRUITING · PHASE2
• An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting — WITHDRAWN
• Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease — COMPLETED
• RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) — COMPLETED · PHASE3
• Clinical Study on the Efficacy and Safety of BAT5906 Injection — COMPLETED · PHASE2
• Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD — COMPLETED · PHASE1
• Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO — TERMINATED · PHASE1
• A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) — COMPLETED · PHASE3
• Efficacy and Safety of RC28-E Versus Aflibercept — OTHER · PHASE3
• ADVM-022 Intravitreal Gene Therapy for Wet AMD — COMPLETED · PHASE1
• First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) — COMPLETED · PHASE1
• Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice — COMPLETED
• Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients — COMPLETED
• Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study — COMPLETED
• A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration — TERMINATED · PHASE1
• Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial — COMPLETED · PHASE1
• This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD — OTHER · PHASE3
• Treat and Extend Analysis Trial With Aflibercept in Wet-AMD — OTHER · PHASE3
• A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) — COMPLETED · PHASE3
• Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration — WITHDRAWN · PHASE1

Refine this search